HGEN News and Press, Humanigen Inc. From 10/06/20

Westwater Resources (WWR) +53%.Xtant Medical Holdings (XTNT) +29% after regaining compliance with NYSE's continued listing standards.Alteryx (AYX) +25% on raising Q3 revenue guidance.CBAK Energy Technology (CBAT) +22%.Ocean Power Technologies (OPTT) +20%.Oxbridge Re Holdin...

Shares of Humanigen (NASDAQ: HGEN) are rising sharply and are up by 23.7% as of 12:14 p.m. EDT on Monday, after climbing by as much as 35.2% earlier today. Investors are bidding up the biopharmaceutical company following its announcement on Friday that lenzilumab, its experimental C...

Gainers: Greenpro Capital (GRNQ) +85%.MyoKardia (MYOK) +58%.Westwater Resources (WWR) +53%.Eidos Therapeutics (EIDX) +40%.Scully Royalty (SRL) +34%.Enlivex Therapeutics (ENLV) +28%.Humanigen (HGEN) +24%.Corvus Pharmaceuticals (CRVS) +22%.Piedmont Lithium (PLL) +22%.Pulse Biosciences (PLS...

Gainers: MyoKardia (MYOK) +58%, Eidos Therapeutics (EIDX) +41%, Enlivex Therapeutics (ENLV) +25%, Humanigen (HGEN) +28%, Corvus Pharmaceuticals (CRVS) +26%.Losers: Xtant Medical Holdings (XTNT) -15%, Curis (CRIS) -7%, Immunome (...

MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals (CRVS) +38% on co-foun...

Humanigen (HGEN) announces patient case report on the use of lenzilumab in critical COVID-19. The published case describes a 77-year-old patient with a past medical history of type II diabetes and heart disorder. The patient tested positive for COVID-19 and was admitted to the ICU in Mar...

Case report demonstrated rapid resolution of hypoxemia and mobility and potential benefit of lenzilumab beyond the initial acute hyper-inflammatory window After 13 weeks of hospitalization, administration of lenzilumab resulted in rapid improvement in oxygenation and subsequent dischar...

Following a type B meeting with the FDA, Humanigen (HGEN) said that the agency has agreed with its current intended submission of lenzilumab in COVID-19 may be sufficient to support an Emergency Use Authorization ((EUA)) request, subject to Phase 3 trial data.The FDA said no material cha...

Type B Meeting With FDA Provided Feedback on Emergency Use Authorization Submission Plans Phase 3 Trial Expanded to Brazil With Seven Sites Actively Enrolling; Patients Already Dosed 17 Active Trial Sites in the US, Including California, Texas and Florida Approval From Mexica...

Humanigen (HGEN) has collaborated with Thermo Fisher Scientific (TMO) to expand the manufacturing capacity for lenzilumab, for use in COVID-19, to support a potential Emergency Use Authorization ((EUA)). "Manufacturing preparation, precision and expertise are critical as we execute on an aggr...